About this Journal Submit a Manuscript Table of Contents
Journal of Toxicology
Volume 2013 (2013), Article ID 956404, 11 pages
http://dx.doi.org/10.1155/2013/956404
Research Article

Differential Cytotoxicity Responses by Dog and Rat Hepatocytes to Phospholipogenic Treatments

1Disposition, Safety and Animal Research, Sanofi, 5 The Mountain Road, Framingham, MA 01701, USA
2Global Safety Assessment, AstraZeneca Pharmaceuticals, B2.86, 35 Gatehouse Drive, Waltham, MA 02451, USA

Received 22 December 2012; Accepted 28 January 2013

Academic Editor: Michael Cunningham

Copyright © 2013 James K. Morelli and Paul J. Ciaccio. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Reasor, K. L. Hastings, and R. G. Ulrich, “Drug-induced phospholipidosis: issues and future directions,” Expert Opinion on Drug Safety, vol. 5, no. 4, pp. 567–583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. W. A. Daniel and J. Wójcikowski, “The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions,” Toxicology and Applied Pharmacology, vol. 158, no. 2, pp. 115–124, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. W. A. Daniel, J. Wójcikowski, and A. Palucha, “Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping,” British Journal of Pharmacology, vol. 134, no. 4, pp. 807–814, 2001. View at Scopus
  4. J. J. Shacka, B. J. Klocke, M. Shibata et al., “Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons,” Molecular Pharmacology, vol. 69, no. 4, pp. 1125–1136, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Kornhuber, A. W. Henkel, T. W. Groemer et al., “Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system,” Journal of Cellular Physiology, vol. 224, no. 1, pp. 152–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Zheng, X. Zhang, and G. R. Rosania, “Effect of phospholipidosis on the cellular pharmacokinetics of chloroquine,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 3, pp. 661–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Reasor and S. Kacew, “Drug-induced phospholipidosis: are there functional consequences?” Experimental Biology and Medicine, vol. 226, no. 9, pp. 825–830, 2001. View at Scopus
  8. M. E. Cartwright, J. Petruska, J. Arezzo et al., “Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects,” Toxicologic Pathology, vol. 37, no. 7, pp. 902–910, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Reasor, K. L. Hastings, and R. G. Ulrich, “Drug-induced phospholipidosis: issues and future directions,” Expert Opinion on Drug Safety, vol. 5, no. 4, pp. 567–583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Reasor, C. M. McCloud, T. L. Beard et al., “Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats,” Toxicology, vol. 106, no. 1–3, pp. 139–147, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Willard, “FDA phospholipidosis working group preliminary results and developing opinions,” Presented at the Society of Toxicology (STP) Continuing Education Course on drug-induced phospholipidosis, 2008.
  12. E. A. Tengstrand, G. T. Miwa, and F. Y. Hsieh, “Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities,” Expert Opinion on Drug Metabolism and Toxicology, vol. 6, no. 5, pp. 555–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. R. Bernstein, J. Morelli, and P. Ciaccio, “Drug-induced phospholipidosis,” Annual Reports in Medicinal Chemistry, vol. 46, pp. 419–429, 2011.
  14. L. R. Barone, S. Boyer, J. R. Damewood Jr., J. Fikes, and P. J. Ciaccio, “Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies,” Journal of Toxicology, vol. 2012, Article ID 308594, 7 pages, 2012. View at Publisher · View at Google Scholar
  15. C. Stenfors, T. Hallerbäck, L. G. Larsson, C. Wallsten, and S. B. Ross, “Pharmacology of a novel selective 5-hydroxytryptamine 1B receptor antagonist, AR-A000002,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 369, no. 3, pp. 330–337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Bernstein, D. Hill, D. Nugiel, E. Pierson, A. Shenvi, and R. Jacobs, “Chroman compounds as 5-HT1B receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy,” PCT Int. Appl. WO 2007053095, 2007.
  17. J. K. Morelli, M. Buehrle, F. Pognan, L. R. Barone, W. Fieles, and P. J. Ciaccio, “Validation of an in vitro screen for phospholipidosis using a high-content biology platform,” Cell Biology and Toxicology, vol. 22, no. 1, pp. 15–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Boya, R. A. Gonzalez-Polo, D. Poncet et al., “Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine,” Oncogene, vol. 22, no. 25, pp. 3927–3936, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Boya, K. Andreau, D. Poncet et al., “Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion,” Journal of Experimental Medicine, vol. 197, no. 10, pp. 1323–1334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Butler, Q. B. Brown, D. J. Chin et al., “Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation,” Rejuvenation Research, vol. 8, no. 4, pp. 227–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Bendiske and B. A. Bahr, “Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis - An approach for slowing Alzheimer disease?” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 5, pp. 451–463, 2003. View at Scopus
  22. V. V. Teplova, A. A. Tonshin, P. A. Grigoriev, N. E. L. Saris, and M. S. Salkinoja-Salonen, “Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions,” Journal of Bioenergetics and Biomembranes, vol. 39, no. 4, pp. 321–329, 2007. View at Publisher · View at Google Scholar · View at Scopus